Benefits and Toxicity of Taxane Addition to Platinum- Fluoropyrimidine Combination in Gastric Cancer Patients with Peritoneal Metastasis
Received Date : 26 May 2022
Accepted Date : 02 Aug 2022
Available Online : 06 Sep 2022
Doi: 10.37047/jos.2022-90537 - Article's Language: EN
J Oncol Sci. 2022;8(3):127-34
This is an open access article under the CC BY-NC-ND license
Objective: In advanced gastric cancer (AGC), peritoneal metastasis (PM) is associated with poor prognosis and worse performance status (PS), which makes chemotherapy administration difficult. However, PM can present with many different clinical pictures. The aim of this study was to investigate the benefits and toxicity of taxane addition to platinum-fluoropyrimidine combination in clinically poor (CPPG) and good prognostic groups (CGPG) of AGC patients with PM. Material and Methods: A total of 172 AGC patients with PM who were treated with taxane plus platinum plus fluoropyrimidine (TPF) or platinum plus fluoropyrimidine (PF) were included in the study. The patients with massive ascites or PS 2-3 or inadequate oral intake were included in the CPPG group, while those with an absence of these clinical factors were included in the CGPG group. The efficacy and toxicity of dose intensity on survival were evaluated separately for each group using the Kaplan-Meier method. Results: At the baseline, 16.9% of all patients had massive ascites, 30.2% had PS of ≥2, and 33.7% had inadequate oral intake. Accordingly, 50.6% of the patients were in CPPG. The overall survival times were found to be similar in patients treated with TPF as well as those treated with PF. Moreover, the addition of taxane treatment did not have any effect on either the poor prognostic group or the good prognostic group. However, as the dose intensity was increased, the grade 3/4 toxicity, dose delay, and reduction rates also increased. Conclusion: Addition of taxane to PF did not contribute to survival in AGC patients with peritoneal metastasis, independent of the clinical prognostic group.
  1. Wei J, Wu ND, Liu BR. Regional but fatal: Intraperitoneal metastasis in gastric cancer. World J Gastroenterol. 2016;22(33):7478-7485. [Crossref]  [PubMed]  [PMC] 
  2. Kus T, Kose F, Aktas G, et al. Prediction of peritoneal recurrence in patients with gastric cancer: a multicenter study. J Gastrointest Cancer. 2021;52(2):634-642. [Crossref]  [PubMed] 
  3. Chau I, Norman AR, Cunningham D, Waters JS, Oates J, Ross PJ. Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer--pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol. 2004;22(12):2395-2403. [Crossref]  [PubMed] 
  4. Kim JG, Ryoo BY, Park YH, et al. Prognostic factors for survival of patients with advanced gastric cancer treated with cisplatin-based chemotherapy. Cancer Chemother Pharmacol. 2008;61(2):301-307. [Crossref]  [PubMed] 
  5. Koo DH, Ryoo BY, Kim HJ, et al. A prognostic model in patients who receive chemotherapy for metastatic or recurrent gastric cancer: validation and comparison with previous models. Cancer Chemother Pharmacol. 2011;68(4):913-921. [Crossref]  [PubMed] 
  6. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al; V325 Study Group. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24(31):4991-4997. [Crossref]  [PubMed] 
  7. Cunningham D, Starling N, Rao S, et al; Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358(1):36-46. [Crossref]  [PubMed] 
  8. Stanley MM, Ochi S, Lee KK, et al. Peritoneovenous shunting as compared with medical treatment in patients with alcoholic cirrhosis and massive ascites. Veterans Administration Cooperative Study on Treatment of Alcoholic Cirrhosis with Ascites. N Engl J Med. 1989;321(24):1632-1638. [Crossref]  [PubMed] 
  9. Lemmens VE, Klaver YL, Verwaal VJ, Rutten HJ, Coebergh JW, de Hingh IH. Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: a population-based study. Int J Cancer. 2011;128(11):2717-2725. [Crossref]  [PubMed] 
  10. März L, Piso P. Treatment of peritoneal metastases from colorectal cancer. Gastroenterol Rep (Oxf). 2015;3(4):298-302. [PubMed]  [PMC] 
  11. Iwasa S, Nakajima TE, Nakamura K, et al. First-line fluorouracil-based chemotherapy for patients with severe peritoneal disseminated gastric cancer. Gastric Cancer. 2012;15(1):21-26. [Crossref]  [PubMed] 
  12. Hara H, Kadowaki S, Asayama M, et al. First-line bolus 5-fluorouracil plus leucovorin for peritoneally disseminated gastric cancer with massive ascites or inadequate oral intake. Int J Clin Oncol. 2018;23(2):275-280. [Crossref]  [PubMed] 
  13. Shirao K, Boku N, Yamada Y, et al; Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group. Randomized Phase III study of 5-fluorouracil continuous infusion vs. sequential methotrexate and 5-fluorouracil therapy in far advanced gastric cancer with peritoneal metastasis (JCOG0106). Jpn J Clin Oncol. 2013;43(10):972-980. [Crossref]  [PubMed] 
  14. Oh SY, Kwon HC, Lee S, et al. A Phase II study of oxaliplatin with low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) for gastric cancer patients with malignant ascites. Jpn J Clin Oncol. 2007;37(12):930-935. [Crossref]  [PubMed] 
  15. Shitara K, Mizota A, Matsuo K, et al. Fluoropyrimidine plus cisplatin for patients with advanced or recurrent gastric cancer with peritoneal metastasis. Gastric Cancer. 2013;16(1):48-55. [Crossref]  [PubMed] 
  16. Arai H, Iwasa S, Boku N, et al. Fluoropyrimidine with or without platinum as first-line chemotherapy in patients with advanced gastric cancer and severe peritoneal metastasis: a multicenter retrospective study. BMC Cancer. 2019;19(1):652. [Crossref]  [PubMed]  [PMC] 
  17. Ohnuma H, Sato Y, Hirakawa M, et al. Docetaxel, cisplatin and S-1 (DCS) combination chemotherapy for gastric cancer patients with peritoneal metastasis: a retrospective study. Cancer Chemother Pharmacol. 2018;81(3):539-548. [Crossref]  [PubMed]